MB203: Eli Lilly Drug Approval, Tesla Deliveries Boost Recovery & What Can Nike Do To Change Their Fortunes

In this episode of Market Bites, the hosts discuss three companies: Eli Lilly, Tesla, and Nike. Neža talks about Eli Lilly's FDA approval for their new Alzheimer's drug and the potential impact on the company's success. Josh dives into Tesla's Q2 delivery numbers, which exceeded expectations and led to a 10% increase in the stock price. Sam discusses Nike's poor earnings and sales forecast, leading to a significant drop in the stock price. The hosts explore the challenges and potential strategies for these companies to turn their fortunes around.

Takeaways

Eli Lilly's FDA approval for their new Alzheimer's drug could significantly contribute to the company's success in the growing Alzheimer therapeutics market.
Tesla's better-than-expected Q2 delivery numbers and improved financial position indicate a potential turnaround for the company.
Nike's poor earnings and sales forecast highlight the challenges the company is facing in a competitive market, but its valuation metrics suggest potential undervaluation.
Competition and changing consumer preferences are impacting big brand names like Nike, Starbucks, and McDonald's, leading to declines in their stock prices.
The upcoming summer of sports events could provide a boost for sports brands like Nike, as consumers are inspired to purchase new athletic gear.

Learn more about trading by visiting the eToro Academy home page where you can read reports, watch videos and sign up to our free trading course.

Your capital is at risk. Other fees apply. For more information, visit etoro.com/trading/fees. Past performance is not an indication of future results.

This communication is for information and education purposes only and should not be taken as investment advice, a personal recommendation, or an offer of, or solicitation to buy or sell, any financial instruments. This material has been prepared without taking into account any particular recipient’s investment objectives or financial situation, and has not been prepared in accordance with the legal and regulatory requirements to promote independent research. Any references to past or future performance of a financial instrument, index or a packaged investment product are not, and should not be taken as, a reliable indicator of future results. eToro makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication.